Research, Charts & Company Announcements
Research Tree offers COUNTRYWIDE PLC research coverage from 1 professional analysts, and we have 3 reports on our platform.
Our simple but effective charting function allows for a quick scan of COUNTRYWIDE PLC's performance over multiple time horizons.
|20/10/2016 12:05:02||London Stock Exchange||Holding(s) in Company|
|11/10/2016 14:30:02||London Stock Exchange||Director/PDMR Shareholding|
|07/10/2016 14:15:02||London Stock Exchange||Director/PDMR Shareholding|
|26/09/2016 17:25:02||London Stock Exchange||Director/PDMR Shareholding|
|22/09/2016 08:00:01||London Stock Exchange||Holdings in Zoopla Property Group PLC|
|07/09/2016 15:00:02||London Stock Exchange||Director/PDMR Shareholding|
|30/08/2016 11:10:02||London Stock Exchange||Holding(s) in Company|
Frequency of research reports
Research reports on COUNTRYWIDE PLC
Providers covering COUNTRYWIDE PLC
Panmure Morning Note 31-07-15
31 Jul 15
We have made further cuts to earnings and dividend estimates partly on the back of the disappointing interim figures and also to reflect higher costs and depreciation charges given the ambitious plans announced to double the business over the period to 2020. While the shares have sold off 4%, lower earnings estimates leaves them trading on a full PE of 14x for the current year. We remain on a hold with a 570 target.
Panmure Morning Note 30-07-15
30 Jul 15
First half PBT of £28.9m was below expectations. Transaction volumes fell by 12% as H1 was adversely affected by the election. The outlook for the housing looks better for the second half though affordability is an increasing issue. We have already taken our FY15 forecasts down in anticipation. The current year PE is 13.8x. We are retaining our hold recommendation and 570p target.
Panmure Morning Note 16-07-15
16 Jul 15
Assuming lower interim profits owing to the election impact, we have cut our forecasts for FY15 by 7% bringing them close to consensus. If there is a strong enough rebound in the second half this may be conservative. The shares are down 10% in the last month and trade on 11.9x FY16 revised earnings. We retain our Hold recommendation and 570p price target given the favourable longer term outlook for the housing market.
Research on related companies
View the latest research on other companies in the sector, published by expert analysts across the city, at some of the best quality Banks, Brokers, and Independent Providers in the market.
Highly concentrated portfolio, strong performance
26 Oct 16
Finsbury Growth & Income Trust (FGT) aims to generate long-term growth in capital and income from a concentrated portfolio of primarily UK equities, which are held for the long term. FGT is benchmarked against the FTSE All-Share index, but is not constrained by its composition; c 70% of the portfolio is invested in consumer stocks. The trust has a progressive dividend policy and annual dividends have compounded by 6.9% pa since FY11; the current dividend yield is 2.0%. FGT has outperformed its peers and the benchmark over one, three, five and 10 years. Strong investor demand along with capital appreciation means the size of the trust has grown significantly; assets under management now approach £1bn.
UK Housebuilding Sector: Q3 2016 - “I am Steve McQueen”
11 Oct 16
Steve was street savvy, but he was not the smartest knife in the drawer, which makes his Delphic comment to Robert Vaughn all the more surprising. What Steve was saying is that “it’s not over yet”; that there is still a lot more to come (sadly for McQueen, who died in 1980 aged 50, it was a future that was not his). The same is true of Brexit and the collateral undulations that it has riven in the UK Housebuilding Sector. Immediately post-the-Brexit-vote, the UK Housebuilding Sector tanked 36% in value in two trading days (24 and 27 June with a weekend in between); and at one stage was off almost 40%.
Acquisition of London & Colonial
21 Oct 16
The acquisition of LCH for up to £5.4m adds a SIPP offer to STM’s portfolio as well as strengthening the group's Life and QROPS books. Employing cash, debt and an element of deferred purchase terms makes the deal usefully earnings-enhancing, adding £0.5m to 2017 estimates. Forecast EPS of 5.9p for 2017 places the shares on a PE multiple of 8.0x, while retaining net cash on the balance sheet leaves the group well positioned to maintain its commitment to a progressive dividend policy.
21 Oct 16
STM* (STM): Acquisition of London & Colonial (CORP) | Hurricane Energy (HUR): £70m placing and open offer (BUY) | Firestone Diamonds* (FDI): Liqhobong commissioning update (BUY) | Accsys (AXS): Acorn aiming to be a mighty oak – analyst interview (BUY) | Avacta* (AVCT): Act now… – analyst interview (CORP) | Tristel* (TSTL): Full year 2016 results – analyst interview (CORP)
N+1 Singer - Morning Song 26-10-2016
26 Oct 16
Verona Pharma has been awarded its second Venture and Innovation Award from the UK Cystic Fibrosis Trust for the development of RPL554 in Cystic Fibrosis (CF). The award signals the significant potential for RPL554 to be developed as a novel treatment for Cystic Fibrosis. Preliminary data supports the molecule’s potential utility in this indication, demonstrating RPL554’S ability to activate an ion channel known to be dysfunctional in CF. The award will support a Phase IIa clinical trial expected to commence in H1 2017. Preparations have also started for Phase IIb trials of RPL554 as a nebulised treatment for COPD with clinical dosing expected to commence in Q2 2017. We remain extremely encouraged by the expanding opportunity of RPL554 and Verona Pharma’s future prospects.